Such a shift towards a more invasive behavior of the tumor might be a reason for GBM recurrence after VEGFA-centered anti-angiogenic therapy, in addition to utilizing alternative pro-angiogenic factors [14], as previously observed in glioma models after blockage of angiogenesis by inhibition of VEGFA signaling [58,59,60]. Here, VEGFA is linked to glioma.